MYC and B-cell non-Hodgkin lymphoma: Here, by performing a concept-driven targeted proteomics and functional analyses, based on the ectopic activation of tissue-specific genes in cancer, we have identified a Rituximab resistance mechanism that operates in aggressive B-cell lymphoma and that is mediated by MYC-driven overexpression of the nuclear factor, CYCLON.